Limited data are available concerning feasibility and toxicity of progenitor cell mobilization and high-dose therapy (HDT) supported by peripheral blood stem cell transplantation (PBSCT) in elderly patients (у60 years) with non-Hodgkin's lymphoma (NHL). From 1995 to 1999, 17 elderly NHL patients (median age 63 years, range 60-70) entered our HDT program and were mobilized with CY (4 g/m 2 ) followed by G-CSF. Mobilization was successful in 13 patients, who then received BEAM or BEAC followed by PBSCT. The feasibility and toxicity of progenitor cell mobilization and HDT in the elderly patients were compared with experiences in 62 NHL patients Ͻ60 years (median 46 years, range 16-59), who received the same mobilization protocol and of whom 48 patients received HDT supported by PBSCT. No significant differences were observed between these groups in the success rate of progenitor cell mobilization, in the number of CD34-positive cells collected or in the number of aphereses needed. HDT appeared to be somewhat more toxic in the elderly patients: a higher peak CRP value (P = 0.08) and longer in-hospital stay (P = 0.05) were observed. No differences were found in transplant-related mortality or severe organ toxicity between these age groups except for oral mucositis grade Ͼ2, which tended to be more common in the elderly patients (P = 0.07). We conclude that progenitor cell mobilization and HDT supported by PBSCT is also feasible in selected elderly patients with NHL. Bone Marrow Transplantation (2000) 26, 737-741.
ied as a part of first-line therapy in NHL patients presenting with poor prognostic features. [2] [3] [4] [5] [6] Due to higher risks associated with the procedure in elderly patients, [7] [8] [9] the use of ASCT has usually been limited to patients aged Ͻ60 years.
The median age of patients with NHL is about 65 years. 10 Previous experiences suggest that older age is associated with poorer prognosis in NHL patients receiving conventional chemotherapy. 11, 12 In fact, age Ͼ60 years is one of the poor prognostic factors in the International Prognostic Index for NHL. 13 Poorer prognosis in elderly patients may be due to more aggressive behaviour of the lymphomas but perhaps more importantly due to host-related reasons, ie the inability of elderly patients to tolerate the therapeutic approaches generally used in younger patients.
Use of mobilized blood stem cells instead of marrow cells for hematopoietic rescue and G-CSF support after progenitor cell infusion have decreased the toxicity associated with HDT during the last decade. HDT supported by PBSCT might also be feasible in selected elderly patients with NHL. We have therefore analyzed our recent experience on HDT supported by PBSCT in NHL patients у60 years of age and compared the feasibility and toxicity of the procedure with those of younger patients (Ͻ60 years) with NHL treated within the same protocol.
Patients and methods
Between January 1995 and December 1999, 82 patients with NHL were entered in the HDT program at the Department of Medicine, Kuopio University Hospital. The patients had either relapsed NHL or were included in the HDT program due to initial poor prognostic features (International Prognostic Index) 13 or based on failure to achieve remission with the first-line chemotherapy.
Eligibility criteria for this study included: (1) progenitor cell mobilization with high-dose CY plus G-CSF, (2) conditioning with BEAM or BEAC, and (3) rescue with mobilized blood progenitor cells followed by G-CSF. Altogether, 79 NHL patients were mobilized with CY plus G-CSF and formed the cohort for this study. Sixty-two patients were Ͻ60 years of age and 17 patients were у60 years. The basic characteristics of these patient groups are presented in Table 1 . 
Mobilization and collection of progenitor cells
The mobilization protocol consisted of intravenous hydration followed by CY 4 g/m 2 in 90 min infusion plus MESNA (day 0). G-CSF (5 g/kg/day) was started on day ϩ2 and continued until leukaphereses were completed or until realization of a mobilization failure. Aphereses were started based on blood CD34 counts. The minimum blood CD34 count to start apheresis was usually Ͼ10 × 10 /kg, which was also used as a minimum criterion for successful progenitor cell mobilization. 
Conditioning regimens

Supportive care
Neutropenic fever was treated with broad-spectrum antibiotics. Fever after progenitor cell mobilization was considered as a low-risk neutropenic fever and treated in most cases with ceftriaxone monotherapy. After HDT, a combination of a betalactam and an aminoglycoside was started when the body temperature rose to 38°C. Later on, the empirical antibiotics were changed if needed according to the results of blood cultures and other available data. In patients with persistent fever Ͼ3 days after the institution of broad-spectrum antibiotics, antifungal therapy with either amphotericin B (0.7 mg/kg/day) or fluconazole (200 mg/day) was started.
Platelet concentrates were transfused when the platelet count fell Ͻ20 ϫ 10 9 /l (the platelet count had to be Ͼ40 ϫ 10 9 /l on the day of the insertion of central venous catheter). Red blood cell concentrates were given to keep the hemoglobin level Ͼ80 g/l.
After progenitor cell infusion, G-CSF (5 g/kg/day) was started and continued until neutrophils were Ͼ1 ϫ 10 9 /l. Prophylaxis for Pneumocystis carinii was started during conditioning and continued for 4 months. No other prophylactic measures were used.
Data collection
Most of the data were gathered from the prospectively collected database on progenitor cell mobilization and HDT supported by PBSC rescue. All patient charts were reviewed for completion of data. For evaluation of the toxicity associated with HDT, WHO grading 14 was used.
Statistical analysis
All analyses were performed by using SPSS 7.0 for Windows (SPSS, Chicago IL, USA). The mean values for the parameters analysed were compared using the Mann-Whitney U test. The chi-square test was used for nominal data. P values Ͼ0.1 are expressed as NS throughout the text. P values Ͼ0.05 and Ͻ0.1 were suggestive of a trend and P values Ͻ0.05 were considered statistically significant.
Results
Feasibility and toxicity of progenitor cell mobilization
Progenitor cell mobilization was successful (Ͼ1.5 × 10 6 /kg CD34-positive cells collected with a single mobilization attempt) in 51/62 younger patients (82%) and in 13/17 elderly patients (77%) (NS). No significant differences were observed in the median number of aphereses or apheresis yields between these age groups ( Table 2 ). No differences in the frequency of neutropenic fever or in the need for supportive care as assessed by need for platelet transfusions were observed either.
Engraftment and supportive care after PBSCT
All 13 elderly patients who were successfully mobilized proceeded to HDT supported by PBSCT. Of the 51 successfully mobilized patients Ͻ60 years, one patient progressed and died soon after progenitor cell collection. Two patients refused HDT after the progenitor cell collection. Fortyeight younger patients were subsequently transplanted after BEAM or BEAC supported by PBSCT. One patient was excluded from the post-transplant analysis exept analysis of transplant-related mortality because of early death (day 0). Data on engraftment and supportive care after PBSCT are presented in Table 3 . No differences were observed in time to engraftment between the different age groups, nor were there differences in need for blood product support. The elderly patients tended to have higher peak CRP values (P = 0.08) and a slightly longer in-hospital stay (P = 0.05) after HDT than did the younger patients.
Infectious complications after high-dose therapy
Although febrile neutropenia was observed in all elderly patients and in 96% of the patients Ͻ60 years, culture-proven septicaemias were far less common. Blood cultures were positive in three elderly patients (23%) (Enterobacter faecium one, Klebsiella pneumoniae one, Staphylococcus epidermidis one). In the younger patients, blood cultures Table 3 High-dose chemotherapy supported by peripheral blood stem cell transplantation in 60 lymphoma patients. Values are medians unless otherwise specified
Age Ͻ60
Age у60 Significance years (n = 47) years (n = 13) 
Toxicity associated with high-dose therapy
Severe toxicities associated with HDT are presented in Table 4 . Oral mucositis ϾWHO grade 2 tended to be more common in the elderly patients (69% vs 38%, P = 0.07). This may be partly due to the higher proportion of patients conditioned with BEAM in the elderly group. In patients Ͻ60 years, 58% of patients conditioned with BEAM had oral mucositis Ͼgrade 2 vs 26% in patients conditioned with BEAC (P = 0.04). Other severe organ toxicities were rare and no differences were observed between the age groups ( Table 4) . Three patients (5%) experienced early transplant-related deaths (TRM 8% in patients у60 years old vs 4% in patients Ͻ60 years, NS). A 64-year old male experienced gram-negative septicemia (Klebsiella pneumoniae) complicated by multi-organ failure and died on day ϩ43 after PBSCT. A 50-year-old male developed fever, hypotension and severe fluid retention during conditioning and died on day 0. A 40-year-old man experienced bacterial and fungal septichaemia (Streptococcus pneumoniae, Candida albicans), developed multi-organ failure and died on day ϩ29 after PBSCT.
Survival
Eight out of 13 elderly patients (62%) are alive with a median follow-up of 16 months (range 6-61ϩ months) (1 May 2000) from PBSCT. In addition to one transplantrelated death, one patient died from secondary acute leukaemia 23 months after PBSCT while in remission for lymphoma. Four patients (30%) have relapsed at 7, 8, 12 and 37 months, respectively. One relapsed patient has only minimal bone marrow infiltration with mantle cells and has not been treated for relapse. The other three relapsed patients have died.
With a median follow-up of 16 months (5-51ϩ months), the overall survival in patients Ͻ60 years is 68%. Two patients died early from transplant-related reasons, one Table 4 Toxicity associated with high-dose chemotherapy in 60 lymphoma patients according to the age of the patients at the time of transplantation 
Discussion
This single center analysis suggests that no major differences exist in the feasibility and toxicity of progenitor cell mobilization and apheresis between elderly and younger lymphoma patients. However, the toxicity associated with HDT supported by PBSCT seems to be increased in elderly patients. To the best of our knowledge this is the first comparison of the feasibility and toxicity of HDT supported by PBSCT between elderly and younger lymphoma patients treated within the same protocol. No significant differences were observed in the success rate or complications associated with progenitor cell mobilization with CY plus G-CSF according to age, nor were there any differences in the time to engraftment. These observations are in line with the study of Guba et al, 15 who observed no differences in the number of CD34-positive cells collected or in the time to engraftment in myeloma patients according to the age.
Two small pilot studies 16, 17 have suggested that PBSCT might also be feasible in selected elderly lymphoma patients. The median ages of the patients in these studies were 62 and 63 years respectively, similar to the present study. In the study reported by Moreau et al, 17 the upper age limit was 65 years. Stamatoullas et al 16 transplanted two patients older than 65 years. Our analysis included four transplanted patients aged 66-70 years and Mazza et al 18 recently reported PBSCT in five NHL patients Ͼ65 years of age (67-76 years). While it may be concluded that PBSCT may be feasible in selected NHL patients aged up to 65 years, very limited published experience is available on this approach in NHL patients over 65 years of age.
Previous studies have reported higher transplant-related toxicity and mortality in elderly patients. [7] [8] [9] The cut-off points for the elderly in these studies have ranged from 50 to 55 years. In these studies, marrow support was used in the majority of patients. Also, a significant proportion of patients received TBI-based conditioning. Both these factors have apparently been responsible for increased toxicity of ASCT observed in the older patient groups. We used a non-TBI based conditioning regimen and blood progenitor cell support followed by G-CSF in order to reduce the toxicity associated with HDT. Even with this approach, the toxicity associated with HDT was somewhat increased in elderly patients.
Older patients are obviously more vulnerable to the effects of conditioning. Another explanation for the higher toxicity observed in elderly patients might be that BEAM conditioning was more commonly used in this group. We looked for severity of mucositis (WHO grade Ͼ2) in patients Ͻ60 years conditioned with either BEAM or BEAC. In this age group, BEAM was associated more commonly with severe mucositis than BEAC. Unfortunately, the number of elderly patients transplanted was too small to draw any meaningful conclusions on the comparative toxicity associated with BEAC or BEAM in this age group.
Another important issue with regard to HDT supported by PBSCT in the elderly NHL patients is long-term outcome. Previous studies 7, 8 indicate that the risk of relapse after ASCT is not increased in elderly patients when compared to matched younger patients. Our preliminary experiences seem to be promising in this respect, but the followup is still relatively short. When compared to younger patients, no early relapses (Ͻ6 months from PBSCT) have been observed in the elderly patients, but this is obviously dependent on patient selection.
Because the majority of lymphoma patients are Ͼ60 years at diagnosis, they inherently have a poorer prognosis when compared to younger patients. If these patients relapse, they usually have a very poor outcome, partly due to toxicity of salvage regimens and partly due to refractoriness of lymphoma. Therefore, HDT supported by PBSCT might also be considered in elderly relapsed lymphoma patients provided that they are otherwise fit. At present there are, however, no randomised studies showing the benefit of HDT over conventional salvage therapy in elderly patients with relapsed NHL.
HDT supported by PBSCT as a part of first-line treatment in NHL patients with poor prognostic features is at present an experimental approach. Given the currently poor treatment results in patients with advanced large cell B, mantle cell or peripheral T cell lymphoma, patients Ͼ60 years might also be considered for clinical trials optimizing current therapies including HDT in these disease entities.
If HDT is to be used in older patients with NHL, there may still be a need for reduced treatment-related toxicity. Theoretically, several points are of interest here. Reduction of toxicity associated with conditioning therapy is a major goal in addition to appropriate patient selection. TBI-based regimens appear not to be suitable for these purposes. Whether BEAM is more toxic than BEAC in this age group is as yet unknown. Experimentally, amifostine has been shown to reduce hematopoietic and mucosal toxicity of melphalan 19 and is now also undergoing clinical trials in patients receiving HDT supported by PBSCT. Higher progenitor cell numbers infused may further decrease the toxicity associated with ASCT. 20 Reduction of mucositis associated with HDT might be of great clinical importance especially in elderly patients. Several interesting agents are under investigation for this purpose. 21 To conclude, HDT supported by PBSCT is feasible in selected NHL patients aged 60 or more, although the toxicity is somewhat higher than in younger patients. More studies are needed to evaluate the long-term efficacy of this approach in elderly patients. There is also still a need to reduce the toxicity of HDT without compromising efficacy.
